honorary doctor at Doctores honoris causa, Faculty of Pharmacy; Doctores honoris causa
Anders Hallberg received his PhD at Lund University in 1980.
He became a full professor in Medicinal Chemistry at Uppsala University in 1990.
He was elected Vice-Chancellor/President at Uppsala University 2006.
Also available at
Anders Hallberg's research interests encompass a range of protein targets of pharmaceutical relevance, including proteases and G-protein coupled receptors (GPCRs). One of the primary themes is to identify novel and selective low molecular weight ligands for these targets. New strategies are developed for both the design and for the synthesis of small, drug-like molecules. Lead compounds are optimized using computer-aided techniques and are preferentially synthesized using high-speed chemistry and new efficient transition metal-catalyzed reactions developed in our laboratory. Considerable efforts have in particular been devoted to the development of new robust and useful palladium-catalyzed C-C bond forming reactions. Major indications that are addressed are the infectious disease Malaria and viral infections caused by HIV and HCV (Hepatitis C Virus). The HCV NS3 protease inhibitor simeprevir (Olysio) launched in US (2013), Japan (2013) and EU (2014) by Medivir/Johnson&Johnson (J&J) originates in part from our research, in close collaboration with Medivir AB, in Sweden. Number of patients treated with simeprevir; > 70 000. In addition, basic research is conducted to identify novel ligands that interfere with protein targets in the renin/angiotensin system. The first drug-like selective and potent angiotensin II, type II receptor (AT2R) agonist (C21) was discovered by our group. Compound C21, owned by Vicore Pharma AB (a company founded by AH) has been extensively studied in vivo and is currently undergoing clinical evaluation (Phase I/II) with first indication idiopathic pulmonary fibrosis. Furthermore, ongoing clinical trials with C21 investigate a potential treatment for Covid-19; the ATTRACT study (Angiotensin II Type Two Receptor Agonist in COVID-19 Trial).
For more details, please see the attached CV, with the list of publications (286) and patents / patent applications (36).
Please contact the directory administrator for the organization (department or similar) to correct possible errors in the information.